Dermatology Specialists Research

Clinical Dermatology Trials

  • Who We Are
    • About
    • Meet Our President/CEO
    • Meet Our Doctors
    • Meet Our Staff
  • Facilities
    • DS Research of Kentucky
    • DS Research of Southern Indiana
    • Travel Accommodations
  • Research Studies
    • ACD Study
    • Other Enrolling Studies
  • Sponsor/CRO
  • News
  • Contact

US FDA Nod for Psoriasis Spray by Dr Reddy’s

February 15, 2016 by admin Leave a Comment

A US subsidiary of Dr Reddy’s laboratory, Promius Pharma, has been successful in getting US FDA approval for its psoriasis spray. This prescription spray, called Sernivo, contains 0.05% betamethasone dipropionate and can be used for external application for psoriasis among patients who are 18 years or over.

“As an emerging leader in the dermatology space, we are committed to developing innovative treatment options and support services for clinicians and patients. The approval of Sernivo emphasizes our ongoing efforts and we look forward to a successful launch of Sernivo Spray in the coming quarter” said Raghav Chari, Executive Vice President of Proprietary Products at Dr. Reddy’s and President of Promius Pharma.

 

Psoriasis:ย 
Psoriasis is a condition in which skin cells begin to multiply rapidly and form silvery scales on skin lesions that are dry, red and patchy. Sometimes, the entire area may be painful. Though medications are available for its treatment, psoriasis in general is difficult to treat.

Approximately, 7.5 million Americans are affected by psoriasis. Therefore, an effective treatment measure would help a considerable number of people. Research has found that untreated and severe psoriasis can increase the risk of cardiovascular disease.

Betamethasone dipropionate:

  • Betamethasone is a strong corticosteroid used to treat a variety of skin conditions.
  • It should not be applied on the face, groin or the under arms
  • It should be applied twice a day on the affected site
  • It can cause itching at the site of application. Treatment should be stopped at this stage.

Facts about the Psoriasis Spray, Sernivo:

  • Contains 0.05% betamethasone dipropionate
  • Can be used by patients who are 18 years or older
  • Should be used only for external application
  • Useful in mild to moderate cases of psoriasis
  • Should not be used for more than 28 days

Clinical Trials using Sernivo:

The benefits of Sernivo were established through two clinical trials. Patients with 10 to 20% psoriasis were included in the study and were asked to either use Sernivo twice a day or its inert vehicle for 28 days.

Results of the Study:

There was significant improvement in psoriasis, in both the trial studies in patients who used Sernivo as compared to those who used the vehicle.

On day 29 in the first study, 42.7% patients were successfully treated after Sernivo while success rate in patients using vehicles was 11.7%.

In study 2, the success rate among patients using Sernivo was 34.5% while in patients using vehicle it was 13.6%

The promising results open the doorway for better treatment and care of psoriasis patients. The US FDA approval is a boost for the Indian pharmaceutical giant, promising to provide innovative solutions to patient care and treatment. The official sales launch will take place later this year.

According to Mr G.V. Prasad, co-chairman and chief executive officer of Dr Reddy’s “The FDA approval of Sernivo Spray is a significant milestone for Promius, as it validates our committed efforts and resources to developing differentiated dermatology products from concept to commercial launch.”

Indian pharmaceutical companies are taking significant steps in the global pharmaceutical market. Recently, Bharat Biotech was in the news for developing a vaccine that might be effective against the Zika virus.

References:

1. http://www.mayoclinic.org/diseases-conditions/psoriasis/basics/symptoms/con-20030838

Source: Medindia

Read more: US FDA Nod for Psoriasis Spray by Dr Reddy’s http://www.medindia.net/news/healthinfocus/us-fda-nod-for-psoriasis-spray-by-dr-reddys-157609-1.htm#ixzz40FuEyOPq

Uncategorized

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Contact Us

DS Research of Kentucky
3810 Springhurst Blvd.
Suite 130
Louisville, KY 40241
O: 502.585.9059
F: 502.585.9708

DS Research of Southern Indiana
1005 E. Lewis & Clark Pkwy
Clarksville, IN 47129
O: 812.213.9769
F: 812.214.7405

Interested About Coming To Us? Our doctors are ready to see you now.

  • This field is for validation purposes and should be left unchanged.

dsresearchtrials

Attention those with vitiligo! Ever experience mo Attention those with vitiligo!

Ever experience more bleeding and bruising after using a vitiligo treatment?

Weโ€™re looking to change that.

Weโ€™re working on a new investigational medication that may minimize common side effects
you might see in treatments on the market.

We currently have PAID vitiligo studies open at both our Kentucky and Southern Indiana locations! ๐Ÿคฉ

Also, donโ€™t forget about our patient referral program! ๐Ÿ’ฐ Refer us someone who might qualify for one of our studies and receive a $25 gift card ๐Ÿ˜
Attention those with vitiligo! Ever experience mo Attention those with vitiligo!

Ever experience more bleeding and bruising after using a vitiligo treatment?

Weโ€™re looking to change that.

Weโ€™re working on a new investigational medication that may minimize common side effects
you might see in treatments on the market.

We currently have vitiligo studies open at both our Kentucky and Southern Indiana locations! ๐Ÿคฉ If you are interested or have any questions please give us a call. ๐Ÿ“ž 

Also, donโ€™t forget about our patient referral program! ๐Ÿ’ฐ Refer us someone who might qualify for one of our studies and receive a $25 gift card ๐Ÿ˜
๐“๐ž๐š๐ฆ ๐Œ๐ž๐ฆ๐›๐ž๐ซ ๐“๐ฎ ๐“๐ž๐š๐ฆ ๐Œ๐ž๐ฆ๐›๐ž๐ซ ๐“๐ฎ๐ž๐ฌ๐๐š๐ฒ! โœจ

๐™ผ๐šŽ๐šŽ๐š ๐š‚๐šŠ๐š›๐šŠ๐š‘, ๐š˜๐šž๐š› ๐š—๐šŽ๐š ๐šŽ๐šœ๐š ๐™ฒ๐š•๐š’๐š—๐š’๐šŒ๐šŠ๐š• ๐š๐šŽ๐šœ๐šŽ๐šŠ๐š›๐šŒ๐š‘ ๐™ฒ๐š˜๐š˜๐š›๐š๐š’๐š—๐šŠ๐š๐š˜๐š›. ๐š†๐šŽ ๐šŠ๐š›๐šŽ ๐šœ๐š˜ ๐šŽ๐šก๐šŒ๐š’๐š๐šŽ๐š ๐šŠ๐š—๐š ๐š•๐šž๐šŒ๐š”๐šข ๐š๐š˜ ๐š‘๐šŠ๐šŸ๐šŽ ๐š‘๐šŽ๐š› ๐Ÿคฉ

#research #dermatology #dermatologyresearch #clinicalresearch #clinicaltrials #teammembertuesday #dermatologist #clinicalresearchcoordinator #alopecia #warts #atopicdermatitis #psoriasis #hs #hidradenitissuppurativa #alopeciaareata #hairloss
๐™„๐™ฉโ€™๐™จ ๐™–๐™ก๐™ก ๐™ž๐™ฃ ๐™ฉ๐™๐™š ๐™„๐™ฉโ€™๐™จ ๐™–๐™ก๐™ก ๐™ž๐™ฃ ๐™ฉ๐™๐™š โœจ๐™™๐™š๐™ฉ๐™–๐™ž๐™ก๐™จโœจ

๐™ƒ๐™–๐™ซ๐™š ๐™ฎ๐™ค๐™ช ๐™จ๐™š๐™š๐™ฃ ๐™ค๐™ช๐™ง ๐™Ž๐™ค๐™ช๐™ฉ๐™๐™š๐™ง๐™ฃ ๐™„๐™‰ ๐™ก๐™ค๐™˜๐™–๐™ฉ๐™ž๐™ค๐™ฃ ๐™ฎ๐™š๐™ฉ? 

๐˜พ๐™ค๐™ข๐™š ๐™จ๐™š๐™š ๐™ช๐™จ ๐™ค๐™ง ๐™œ๐™ž๐™ซ๐™š ๐™ช๐™จ ๐™– ๐™˜๐™–๐™ก๐™ก ๐™ฉ๐™ค ๐™ก๐™š๐™–๐™ง๐™ฃ ๐™ข๐™ค๐™ง๐™š ๐™–๐™—๐™ค๐™ช๐™ฉ ๐™ฉ๐™๐™š ๐™˜๐™ช๐™ง๐™ง๐™š๐™ฃ๐™ฉ ๐™ฅ๐™–๐™ž๐™™ ๐™˜๐™ก๐™ž๐™ฃ๐™ž๐™˜๐™–๐™ก ๐™ฉ๐™ง๐™ž๐™–๐™ก๐™จ ๐™ฌ๐™š ๐™๐™–๐™ซ๐™š ๐™ค๐™ฅ๐™š๐™ฃ!

๐Ÿ“๐—ž๐—ฒ๐—ป๐˜๐˜‚๐—ฐ๐—ธ๐˜†: ๐Ÿฑ๐Ÿฌ๐Ÿฎ-๐Ÿฑ๐Ÿต๐Ÿฑ-๐Ÿต๐Ÿฌ๐Ÿฑ๐Ÿต
๐Ÿ“๐—ฆ๐—ผ๐˜‚๐˜๐—ต๐—ฒ๐—ฟ๐—ป ๐—œ๐—ก: ๐Ÿด๐Ÿญ๐Ÿฎ-๐Ÿฎ๐Ÿญ๐Ÿฏ-๐Ÿต๐Ÿณ๐Ÿฒ๐Ÿต
Load More... Follow on Instagram

Copyright © 2025 Dermatology Specialists Research :: Clinical Dermatology Trials

Privacy Policy
  • Facebook
  • Instagram
  • LinkedIn